108 related articles for article (PubMed ID: 19656552)
1. An analysis of clinical outcomes of 91 pregnancies in 83 women treated with danaparoid (Orgaran).
Magnani HN
Thromb Res; 2010 Apr; 125(4):297-302. PubMed ID: 19656552
[TBL] [Abstract][Full Text] [Related]
2. Treatment of 51 pregnancies with danaparoid because of heparin intolerance.
Lindhoff-Last E; Kreutzenbeck HJ; Magnani HN
Thromb Haemost; 2005 Jan; 93(1):63-9. PubMed ID: 15630492
[TBL] [Abstract][Full Text] [Related]
3. Heparin-induced thrombocytopenia (HIT). A report of 1,478 clinical outcomes of patients treated with danaparoid (Orgaran) from 1982 to mid-2004.
Magnani HN; Gallus A
Thromb Haemost; 2006 Jun; 95(6):967-81. PubMed ID: 16732376
[TBL] [Abstract][Full Text] [Related]
4. [Danaparoid in pregnancy in cases of heparin intolerance - use in 59 cases].
Schindewolf M; Magnani HN; Lindhoff-Last E
Hamostaseologie; 2007 May; 27(2):89-97. PubMed ID: 17479171
[TBL] [Abstract][Full Text] [Related]
5. On the prophylactic and therapeutic use of danaparoid sodium (Orgaran) in patients with heparin-induced thrombocytopenia.
Schenk JF; Pindur G; Stephan B; Mörsdorf S; Mertzlufft F; Kroll H; Wenzel E; Seyfert UT
Clin Appl Thromb Hemost; 2003 Jan; 9(1):25-32. PubMed ID: 12643320
[TBL] [Abstract][Full Text] [Related]
6. Comparing subcutaneous danaparoid with intravenous unfractionated heparin for the treatment of venous thromboembolism. A randomized controlled trial.
de Valk HW; Banga JD; Wester JW; Brouwer CB; van Hessen MW; Meuwissen OJ; Hart HC; Sixma JJ; Nieuwenhuis HK
Ann Intern Med; 1995 Jul; 123(1):1-9. PubMed ID: 7539233
[TBL] [Abstract][Full Text] [Related]
7. Management of heparin allergy during pregnancy with danaparoid.
Harrison SJ; Rafferty I; McColl MD
Blood Coagul Fibrinolysis; 2001 Mar; 12(2):157-9. PubMed ID: 11302479
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of danaparoid (Orgaran) use in children.
Bidlingmaier C; Magnani HN; Girisch M; Kurnik K
Acta Haematol; 2006; 115(3-4):237-47. PubMed ID: 16549902
[TBL] [Abstract][Full Text] [Related]
9. Danaparoid is effective and safe for patients with obstetric antiphospholipid syndrome.
Yoshihara H; Sugiura-Ogasawara M; Kitaori T; Katano K; Ozaki Y
Mod Rheumatol; 2020 Mar; 30(2):332-337. PubMed ID: 30924705
[No Abstract] [Full Text] [Related]
10. A comparative review of the adverse effect profiles of heparins and heparinoids.
Borris LC; Lassen MR
Drug Saf; 1995 Jan; 12(1):26-31. PubMed ID: 7537967
[TBL] [Abstract][Full Text] [Related]
11. A review of 122 published outcomes of danaparoid anticoagulation for intermittent haemodialysis.
Magnani HN
Thromb Res; 2010 Apr; 125(4):e171-6. PubMed ID: 19926118
[TBL] [Abstract][Full Text] [Related]
12. Danaparoid sodium.
Acostamadiedo JM; Iyer UG; Owen J
Expert Opin Pharmacother; 2000 May; 1(4):803-14. PubMed ID: 11249517
[TBL] [Abstract][Full Text] [Related]
13. Low molecular weight heparinoid, ORG 10172 (danaparoid), and outcome after acute ischemic stroke: a randomized controlled trial. The Publications Committee for the Trial of ORG 10172 in Acute Stroke Treatment (TOAST) Investigators.
JAMA; 1998 Apr 22-29; 279(16):1265-72. PubMed ID: 9565006
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of danaparoid sodium (ORG 10172) in critically ill patients with heparin-associated thrombocytopenia.
Tardy-Poncet B; Tardy B; Reynaud J; Mahul P; Mismetti P; Mazet E; Guyotat D
Chest; 1999 Jun; 115(6):1616-20. PubMed ID: 10378558
[TBL] [Abstract][Full Text] [Related]
15. Danaparoid. A review of its pharmacology and clinical use in the management of heparin-induced thrombocytopenia.
Wilde MI; Markham A
Drugs; 1997 Dec; 54(6):903-24. PubMed ID: 9421696
[TBL] [Abstract][Full Text] [Related]
16. Results of a systematic evaluation of treatment outcomes for heparin-induced thrombocytopenia in patients receiving danaparoid, ancrod, and/or coumarin explain the rapid shift in clinical practice during the 1990s.
Lubenow N; Warkentin TE; Greinacher A; Wessel A; Sloane DA; Krahn EL; Magnani HN
Thromb Res; 2006; 117(5):507-15. PubMed ID: 15907979
[TBL] [Abstract][Full Text] [Related]
17. Use of danaparoid sodium (Orgaran) as an alternative to heparin sodium during cardiopulmonary bypass: a clinical evaluation of six cases.
Fernandes P; Mayer R; MacDonald JL; Cleland AG; Hay-McKay C
Perfusion; 2000 Nov; 15(6):531-9. PubMed ID: 11131218
[TBL] [Abstract][Full Text] [Related]
18. Danaparoid for heparin-induced thrombocytopenia: an analysis of treatment failures.
Kodityal S; Manhas AH; Udden M; Rice L
Eur J Haematol; 2003 Aug; 71(2):109-13. PubMed ID: 12890149
[TBL] [Abstract][Full Text] [Related]
19. Danaparoid: a review of its use in thromboembolic and coagulation disorders.
Ibbotson T; Perry CM
Drugs; 2002; 62(15):2283-314. PubMed ID: 12381232
[TBL] [Abstract][Full Text] [Related]
20. Prospective randomised open-label comparison of danaparoid with dextran 70 in the treatment of heparin-induced thrombocytopaenia with thrombosis: a clinical outcome study.
Chong BH; Gallus AS; Cade JF; Magnani H; Manoharan A; Oldmeadow M; Arthur C; Rickard K; Gallo J; Lloyd J; Seshadri P; Chesterman CN;
Thromb Haemost; 2001 Nov; 86(5):1170-5. PubMed ID: 11816702
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
